DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Congestive Heart Failure market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congestive Heart Failure Market Forecast

Some of the key facts of the Congestive Heart Failure Market Report: 

• The Congestive Heart Failure market size was valued USD 6,741 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In August 2021, Boehringer Ingelheim and Eli Lilly reported that Jardiance (empagliflozin) 10 mg, which the US FDA approved, has decreased the risk of cardiovascular death as well as heart failure hospitalisation in individuals with heart failure with reduced ejection fraction (HFrEF)
• In February 2021, The following additional indication for Entresto (sacubitril/valsartan) was approved by the US FDA, according to a Novartis press release: to lower the risk of cardiovascular death and heart failure hospitalisation in adult patients with chronic heart failure. Patients with a left ventricular rejection fraction (LVEF) below normal will see the benefits the greatest
• According to the DelveInsight estimate, there will be 6,543,570 cases of heart failure overall in the US in 2021. In the US, there will be 5,234,856 diagnosed instances of heart failure overall in 2021, according to estimates
• Women tend to experience heart failure at an older age than males do, and it is a significant cause of morbidity and mortality in women. The analysis estimates that there were 2,512,731 male and 2,722,125 female HF cases in the US in 2021, and that number is anticipated to rise during the study period (2019–2032)
• Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, CardioKine Inc, NovaCardia, Inc., GlaxoSmithKline, Bristol-Myers Squibb, Advanz Pharma, Solvay Pharmaceuticals, Abbott, Otsuka Pharma, Takeda, AstraZeneca, and others
• Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), Lixivaptan, KW-3902IV, carvedilol, Irbesartan, Oxypurinol, SLV320, Levosimendan, OPC-61815 injection, MCC-135, AC2592, and others
• The Congestive Heart Failure epidemiology based on gender analyzed that heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age compared to men
• The Congestive Heart Failure market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congestive Heart Failure pipeline products will significantly revolutionize the Congestive Heart Failure market dynamics.

Congestive Heart Failure Overview

Congestive heart failure (HF) is another name for HF. It can also be divided into right-side HF (occurs when the heart is unable to fill itself with adequate blood) and left-side HF (occurs when the heart is unable to pump enough oxygen-rich blood to the body). Cor pulmonale is another word for heart failure and denotes that the right-side heart failure is brought on by elevated blood pressure in the pulmonary arteries and right ventricle.

Get a Free sample for the Congestive Heart Failure Market Report 

https://www.delveinsight.com/report-store/congestive-heart-failure-market

Congestive Heart Failure Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congestive Heart Failure Epidemiology Segmentation:

The Congestive Heart Failure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Congestive Heart Failure
• Prevalent Cases of Congestive Heart Failure by severity
• Gender-specific Prevalence of Congestive Heart Failure
• Diagnosed Cases of Episodic and Chronic Congestive Heart Failure

Download the report to understand which factors are driving Congestive Heart Failure epidemiology trends @ Congestive Heart Failure Epidemiology Forecast

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congestive Heart Failure Therapies and Key Companies

• OPC-61815: Otsuka pharmaceuticals
• Omecamtivmecarbil: Cytokinetics
• AZD4831: AstraZeneca
• AT-001: Applied Therapeutics
• Rexlemestrocel-L (Revascor: Mesoblast
• Finerenone (Kerendia): Bayer
• Finerenone (Kerendia): Novo Nordisk
• Sotagliflozin: Lexicon Pharmaceuticals
• Furoscix(furosemide injection): scPharmaceuticals
• Lixivaptan: CardioKine Inc
• KW-3902IV: NovaCardia, Inc.
• carvedilol: GlaxoSmithKline
• Irbesartan: Bristol-Myers Squibb
• Oxypurinol: Advanz Pharma
• SLV320: Solvay Pharmaceuticals
• Levosimendan: Abbott
• OPC-61815 injection: Otsuka Pharma
• MCC-135: Takeda
• AC2592: AstraZeneca

Discover more about therapies set to grab major Congestive Heart Failure market share @ Congestive Heart Failure Treatment Market

Congestive Heart Failure Market Drivers

• Robust emerging pipeline
• Recent approval of therapies and promising emerging therapies
• Evidence-based therapies
• Aging of the population
• Rising prevalence of the disease

Congestive Heart Failure Market Barriers

• Availability of generic and off-label therapies in the market setting
• Lack of confidence in diagnosis and management
• Treatment failure to stimulate and follow society’s goals and requirements

Scope of the Congestive Heart Failure Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, CardioKine Inc, NovaCardia, Inc., GlaxoSmithKline, Bristol-Myers Squibb, Advanz Pharma, Solvay Pharmaceuticals, Abbott, Otsuka Pharma, Takeda, AstraZeneca, and others
• Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), Lixivaptan, KW-3902IV, carvedilol, Irbesartan, Oxypurinol, SLV320, Levosimendan, OPC-61815 injection, MCC-135, AC2592, and others
• Congestive Heart Failure Therapeutic Assessment: Congestive Heart Failure current marketed and Congestive Heart Failure emerging therapies
• Congestive Heart Failure Market Dynamics: Congestive Heart Failure market drivers and Congestive Heart Failure market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Congestive Heart Failure Unmet Needs, KOL’s views, Analyst’s views, Congestive Heart Failure Market Access and Reimbursement 

To know more about Congestive Heart Failure companies working in the treatment market, visit @ Congestive Heart Failure Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Congestive Heart Failure Market Report Introduction

2. Executive Summary for Congestive Heart Failure

3. SWOT analysis of Congestive Heart Failure

4. Congestive Heart Failure Patient Share (%) Overview at a Glance

5. Congestive Heart Failure Market Overview at a Glance

6. Congestive Heart Failure Disease Background and Overview

7. Congestive Heart Failure Epidemiology and Patient Population

8. Country-Specific Patient Population of Congestive Heart Failure 

9. Congestive Heart Failure Current Treatment and Medical Practices

10. Congestive Heart Failure Unmet Needs

11. Congestive Heart Failure Emerging Therapies

12. Congestive Heart Failure Market Outlook

13. Country-Wise Congestive Heart Failure Market Analysis (2019–2032)

14. Congestive Heart Failure Market Access and Reimbursement of Therapies

15. Congestive Heart Failure Market Drivers

16. Congestive Heart Failure Market Barriers

17.  Congestive Heart Failure Appendix

18. Congestive Heart Failure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services